R&D

CVDHKG: 3696

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 — a potent, highly selective, oral small‑molecule inhibitor powered by AI — as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a),…

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases

Biocytogen Launches RenSuper Workstation, AI-Driven Antibody Discovery Platform to Transform Therapeutic Development

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Simcere Halts R&D on Alzheimer's Drug Candidates Amid Pipeline Setbacks
Clinical trial resultsHKG: 2096

Simcere Halts R&D on Alzheimer’s Drug Candidates Amid Pipeline Setbacks

Ascletis Pharma's ASC47 Outperforms Semaglutide in Weight Loss Study
Ascletis PharmaCombination therapy

Ascletis Pharma’s ASC47 Outperforms Semaglutide in Weight Loss Study

Legend Biotech Corporation
BiotechCAR-T

Legend Biotech Corporation to Establish Advanced R&D Center in Philadelphia for Next-Generation Cell Therapies

BayerBiotech

Bayer AG Launches New Life Sciences Incubator in Shanghai to Boost Biotech Ecosystem

Show More